FGTI-2734
FGTI-2734 is a RAS C-terminal mimetic dual farnesyl transferase (FT) and geranylgeranyl transferase-1 (GGT-1) inhibitor with IC50s of 250 nM and 520 nM for FT and GGT-1, respectively. FGTI-2734 can prevent membrane localization of KRAS, hence solving KRAS resistance problem and thwarting mutant KRAS patient-derived pancreatic tumors[1].
Product Specifications
CAS Number
1247018-19-4
UNSPSC
12352005
Target
Farnesyl Transferase
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/fgti-2734.html
Concentration
10mM
Purity
99.85
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
O=S(C1=NC=CC=C1)(N(CCN(C2=CC=C(C#N)C=C2F)CC3=CN=CN3C)CC4CCCCC4)=O
Molecular Formula
C26H31FN6O2S
Molecular Weight
510.63
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, stored under nitrogen)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
CD44 Standard (156-3C11), CF740 conjugate, 0.1mg/mL
Napsin A (Lung Adenocarcinoma Marker) (rNAPSA/1239), CF405S conjugate, 0.1mg/mL
EGFRvIII (Epidermal Growth Factor Receptor, Variant III) (GFR/2600R), CF568 conjugate, 0.1mg/mL
MiTF (Microphthalmia Transcription Factor) (MITF/915), CF647 conjugate, 0.1mg/mL
